KYTX

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kyverna Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Kyverna Therapeutics Inc. EPS for the last quarter amounts to -0.85 USD, increased 6.25 % YoY.

Kyverna Therapeutics Inc (KYTX) has 112 emplpoyees as of December 16 2025.

Today KYTX has the market capitalization of 473.66M USD.